NanoRepro AG Sees Strong Paedi Protect Sales and New Drugstore Listing

NanoRepro AG recently published its H1 2026 report, highlighting robust sales for its Paedi Protect line and securing a drugstore listing for newkee products. The Paedi Protect sales exceeded expectations, reaching €10.9 million, attributed to increased demand for sunscreen in a warm June. However, the company faced an 11.5% decline in its rapid testing kits sales.

Despite a weaker topline, NanoRepro reduced its EBITDA loss to € -0.8 million, achieving cost efficiencies through better procurement and reduced marketing expenses. A new drugstore listing for newkee is set to expand sales channels, potentially adding €1-2 million annually.

NanoRepro maintains its sales targets for the coming years and confirms a "BUY" recommendation with a target price of € 4.40.